{"transactions":[{"id":1870163,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T20:31:44.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in equal monthly installments over 12 months following May 31, 2023 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":5.63,"expiration_date":"2033-05-30","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-033785","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919123033785/doc4.xml","form_type":"4"}},{"id":2230095,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-16T21:17:23.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in equal monthly installments over 12 months following June 15, 2022 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":13.69,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-22-037525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919122037525/doc4.xml","form_type":"4"}},{"id":2321674,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-22T23:26:18.000Z","date":"2022-03-22","kind":"sale","acquired":false,"shares":1455,"price":18.6292,"value":27105.486,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $18.51 to $18.835, inclusive.  The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C.  Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P.  Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest."}],"balance_after":4129950,"source":{"system":"sec-edgar","filing":"0001209191-22-020637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919122020637/doc4.xml","form_type":"4"}},{"id":2321673,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-22T23:26:18.000Z","date":"2022-03-21","kind":"sale","acquired":false,"shares":24000,"price":19.01,"value":456240.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $19.00 to $19.30, inclusive.  The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C.  Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P.  Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest."}],"balance_after":4131405,"source":{"system":"sec-edgar","filing":"0001209191-22-020637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919122020637/doc4.xml","form_type":"4"}},{"id":2321672,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-22T23:26:18.000Z","date":"2022-03-18","kind":"sale","acquired":false,"shares":13200,"price":20.34,"value":268488.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $20.00 to $20.70, inclusive.  The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C.  Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P.  Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest."}],"balance_after":4155405,"source":{"system":"sec-edgar","filing":"0001209191-22-020637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919122020637/doc4.xml","form_type":"4"}},{"id":2321671,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-22T23:26:18.000Z","date":"2022-03-18","kind":"sale","acquired":false,"shares":552225,"price":19.04,"value":10514364.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $19.00 to $19.8726, inclusive.  The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C.  Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P.  Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest."}],"balance_after":4168605,"source":{"system":"sec-edgar","filing":"0001209191-22-020637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919122020637/doc4.xml","form_type":"4"}},{"id":2563801,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-21T00:10:08.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":6635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over three (3) years, with one-third (1/3) of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reporting person holds these securities for the benefit of Quan Venture Fund I, L.P. (\"Quan Capital\"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The reporting person is amanager of Quan Venture Partners I, L.L.C. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest. This report on Form 4 shall not be deemed anadmission the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":6635,"derivative":{"exercise_price":11.07,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":6635},"source":{"system":"sec-edgar","filing":"0001179110-21-008866","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000117911021008866/edgar.xml","form_type":"4/A","original_submission_date":"2021-07-06"}},{"id":2640535,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-06T22:05:53.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":6635,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reporting person holds these securities for the benefit of Quan Venture Fund I, L.P. (\"Quan Capital\"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The reporting person is a manager of Quan Venture Partners I, L.L.C. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest. This report on Form 4 shall not be deemed an admission the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":6635,"derivative":{"exercise_price":11.07,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":6635},"source":{"system":"sec-edgar","filing":"0001140361-21-023544","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121023544/form4.xml","form_type":"4"}},{"id":2651259,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-06-30T01:56:06.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":579710,"ownership":{"direct":false,"nature":"By Quan Venture Fund I, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This amount includes 104,176 shares that were acquired upon conversion of 3,235,294 shares of Tempest, which Quan Capital agreed to purchase at a purchase price of $0.85 per share pursuant to a Funding Agreement with Tempest, which was conditioned upon the satisfaction or waiver of the conditions to Closing."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Millendo Therapeutics, Inc. (\"Millendo\") and private company Tempest Therapeutics, Inc. (\"Tempest\"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the \"Merger Agreement\"), which closed on June 25, 2021 (\"Closing\"), each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed \"Tempest Therapeutics, Inc.\""},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record held by Quan Venture Fund I, L.P. (\"Quan Capital\"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The Reporting Person is a manager of Quan Venture Partners I, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Capital. The Reporting Person disclaims beneficial ownership of the shares held by Quan Capital, except to the extent of any pecuniary interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Quan Capital and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or her pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":579710,"source":{"system":"sec-edgar","filing":"0001140361-21-022786","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000114036121022786/form4.xml","form_type":"4"}},{"id":2653038,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-28T22:16:25.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":14250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 24, 2022 and the date of the 2022 Annual Meeting of Stockholders."}],"balance_after":14250,"derivative":{"exercise_price":8.21,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":14250},"source":{"system":"sec-edgar","filing":"0001567619-21-012670","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661059/000156761921012670/doc1.xml","form_type":"4"}},{"id":2764499,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-04-01T22:19:57.000Z","date":"2021-03-30","kind":"exercise","acquired":false,"shares":458016,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C.  Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P.  Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":280991},"source":{"system":"sec-edgar","filing":"0001209191-21-024234","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919121024234/doc4.xml","form_type":"4"}},{"id":2764498,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-04-01T22:19:57.000Z","date":"2021-03-30","kind":"exercise","acquired":false,"shares":7236938,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C.  Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P.  Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4439839},"source":{"system":"sec-edgar","filing":"0001209191-21-024234","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919121024234/doc4.xml","form_type":"4"}},{"id":2764497,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T22:19:57.000Z","date":"2021-03-30","kind":"purchase","acquired":true,"shares":10000,"price":20,"value":200000.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were purchased in the Issuer's initial public offering."}],"balance_after":4730830,"source":{"system":"sec-edgar","filing":"0001209191-21-024234","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919121024234/doc4.xml","form_type":"4"}},{"id":2764496,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T22:19:57.000Z","date":"2021-03-30","kind":"exercise","acquired":true,"shares":280991,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C.  Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P.  Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest."}],"balance_after":4720830,"source":{"system":"sec-edgar","filing":"0001209191-21-024234","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919121024234/doc4.xml","form_type":"4"}},{"id":2764495,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T22:19:57.000Z","date":"2021-03-30","kind":"exercise","acquired":true,"shares":4439839,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C.  Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P.  Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest."}],"balance_after":4439839,"source":{"system":"sec-edgar","filing":"0001209191-21-024234","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919121024234/doc4.xml","form_type":"4"}},{"id":2769437,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-03-29T22:31:49.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in equal monthly installments over the 12 months following March 25, 2021."}],"balance_after":15000,"derivative":{"exercise_price":20,"expiration_date":"2031-03-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-023472","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919121023472/doc4.xml","form_type":"4"}},{"id":3110055,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-15T21:47:52.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":14250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders."}],"balance_after":14250,"derivative":{"exercise_price":24.13,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":14250},"source":{"system":"sec-edgar","filing":"0001123292-20-000885","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661059/000112329220000885/edgar.xml","form_type":"4"}},{"id":3487246,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-18T00:20:12.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three equal annual installments beginning on June 13, 2020."}],"balance_after":22000,"derivative":{"exercise_price":15.57,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001123292-19-000886","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661059/000112329219000886/edgar.xml","form_type":"4"}},{"id":3529145,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2019-05-13T23:32:31.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":7861636,"ownership":{"direct":false,"nature":"By Quan Venture Fund II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":978570},"source":{"system":"sec-edgar","filing":"0001123292-19-000750","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1661059/000112329219000750/edgar.xml","form_type":"4"}},{"id":3529144,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T23:32:31.000Z","date":"2019-05-13","kind":"purchase","acquired":true,"shares":125000,"price":15,"value":1875000.0,"ownership":{"direct":false,"nature":"By Quan Venture Fund II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P. except to the extent of her pecuniary interest therein."}],"balance_after":1103570,"source":{"system":"sec-edgar","filing":"0001123292-19-000750","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661059/000112329219000750/edgar.xml","form_type":"4"}},{"id":3529143,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T23:32:31.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":978570,"ownership":{"direct":false,"nature":"By Quan Venture Fund II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P. except to the extent of her pecuniary interest therein."}],"balance_after":978570,"source":{"system":"sec-edgar","filing":"0001123292-19-000750","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661059/000112329219000750/edgar.xml","form_type":"4"}},{"id":3885181,"issuer":{"id":12201,"kind":"organization","name":"ARMO BioSciences, Inc.","symbol":"ARMO"},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-22T19:34:10.000Z","date":"2018-06-22","kind":"disposition_to_issuer","acquired":false,"shares":18000,"price":10.03,"value":180540.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option, which provided for vesting in thirty-six equal monthly installments following March 31, 2018, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":39.97,"expiration_date":"2028-03-25","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000899243-18-017785","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693664/000089924318017785/doc4.xml","form_type":"4"}},{"id":3885180,"issuer":{"id":12201,"kind":"organization","name":"ARMO BioSciences, Inc.","symbol":"ARMO"},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-22T19:34:10.000Z","date":"2018-06-22","kind":"other","acquired":false,"shares":404900,"price":50,"value":20245000.0,"ownership":{"direct":false,"nature":"By Quan Venture Fund I, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Bluegill Acquisition Corporation (\"Merger Sub\"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the \"Offer\") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the \"Offer Price\"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These Shares are held of record held by Quan Venture Fund I, L.P. (\"Quan Capital\"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The Reporting Person is a manager of Quan Venture Partners I, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Capital. The Reporting Person disclaims beneficial ownership of the shares held by Quan Capital, except to the extent of her pecuniary interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Quan Capital and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or her pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-017785","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693664/000089924318017785/doc4.xml","form_type":"4"}},{"id":3980961,"issuer":{"id":12201,"kind":"organization","name":"ARMO BioSciences, Inc.","symbol":"ARMO"},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-03-28T16:56:37.000Z","date":"2018-03-26","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares of common stock subject to the option vest on the last day of the calendar month in which the option was granted, and 1/36th of the shares subject to the option vest on the last day of the 35 calendar months immediately thereafter."}],"balance_after":18000,"derivative":{"exercise_price":39.97,"expiration_date":"2028-03-25","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000899243-18-008734","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693664/000089924318008734/doc4.xml","form_type":"4"}},{"id":4084911,"issuer":{"id":12201,"kind":"organization","name":"ARMO BioSciences, Inc.","symbol":"ARMO"},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C-1 Convertible Preferred Stock","published_at":"2018-01-30T17:09:05.000Z","date":"2018-01-30","kind":"exercise","acquired":false,"shares":404900,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Quan Venture Fund I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering.   The Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering.   The Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering.   The Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Shares are held of record held by Quan Venture Fund I, L.P. (Quan Capital). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The Reporting Person is a manager of Quan Venture Partners I, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Capital. The Reporting Person disclaims beneficial ownership of the shares held by Quan Capital, except to the extent of her pecuniary interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Quan Capital and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or her pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":404900},"source":{"system":"sec-edgar","filing":"0000899243-18-002283","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693664/000089924318002283/doc4.xml","form_type":"4"}},{"id":4084910,"issuer":{"id":12201,"kind":"organization","name":"ARMO BioSciences, Inc.","symbol":"ARMO"},"owners":[{"id":112819,"kind":"person","name":"Xu Stella","position":1,"cik":"0001728741","reported_name":"Xu Stella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-30T17:09:05.000Z","date":"2018-01-30","kind":"exercise","acquired":true,"shares":404900,"ownership":{"direct":false,"nature":"By Quan Venture Fund I, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The total represents shares received upon conversion of shares of Series C-1 Convertible Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering.   The Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Shares are held of record held by Quan Venture Fund I, L.P. (Quan Capital). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The Reporting Person is a manager of Quan Venture Partners I, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Capital. The Reporting Person disclaims beneficial ownership of the shares held by Quan Capital, except to the extent of her pecuniary interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Quan Capital and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or her pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":404900,"source":{"system":"sec-edgar","filing":"0000899243-18-002283","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693664/000089924318002283/doc4.xml","form_type":"4"}}]}